AmCAD-CA
Computer-aided detection system for medical imaging
Software · OtherCompany source
Company profile
About AmCad BioMed
AmCad BioMed Corporation, founded in 2008 and publicly traded on the Taipei Exchange (Ticker: 4188), is a pioneering medical imaging AI company specializing in ultrasound-based diagnostic solutions. Headquartered in Taiwan, the company develops patented artificial intelligence technologies that integrate with ultrasound imaging to support early disease detection and improve diagnostic consistency across multiple clinical applications. The company's flagship products include AmCAD-UO for obstructive sleep apnea assessment, AmCAD-UT for thyroid nodule evaluation, AmCAD-UB for breast imaging with BI-RADS insights, and AmCAD-US for general soft tissue analysis. AmCad BioMed delivered the world's first ultrasound AI solution and holds multiple FDA and CE certifications for its products. The company's technology enables real-time quantification and visualization during ultrasound examinations, helping clinicians detect diseases faster and interpret images with greater accuracy. AmCad BioMed serves over 130 healthcare institutions worldwide, addressing critical diagnostic challenges including the 30% of thyroid nodules that are indeterminate by conventional ultrasound, the 80% of OSA cases that go undiagnosed, and the 50% of breast cancers missed in women with dense breast tissue. The company maintains strong commitments to research and development, ESG principles, and expanding global access to smart healthcare solutions, including through handheld ultrasound systems for underserved and remote areas.
Company description AmCad BioMed official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at AmCad BioMed?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast lesions
- Obstructive Sleep Apnea (OSA)
- Soft tissue abnormalities
- Thyroid nodules
Who it serves
- Clinics
- Health Systems
- Hospitals
Deployment & integration
Embedded · Other deployment with recorded integration context.
Geographic context
MarketsEurope · Global (over 130 healthcare institutions worldwide) · Middle East (Dubai presence) · Taiwan · USA
Company sourceOfficial website
Company milestones
Platform expansion
Published research in Sleep Medicine journal with Stanford Sleep Center (2025). Published study in Otolaryngology–Head and Neck Surgery with Bern University Hospital showing AmCAD-UO's value in predicting OSA treatment success. Launched handheld ultrasound (POCUS) system with AI guidance (2024). Organized 28 clinical education sessions, 9 academic exchanges, and 5 corporate health screening programs in 2024. Exhibited at WDSS, World Sleep 2025, ISSS 2024.
Partnerships
Recorded partners
- Bern University Hospital
- Chang Gung Memorial Hospital
- National Taiwan University Hospital
- Stanford Sleep Center
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
AmCAD-UB
Enhance breast ultrasound scans with BI-RADS insights
Software · OtherCompany source
AmCAD-UO
Redefine OSA assessment and treatment with ultrasound AI
Software · OtherCompany source
AmCAD-US
Unlock soft tissue insights in various organs
Software · OtherCompany source
AmCAD-UT
Accelerate Thyroid ultrasound exams with real-time intelligence
Software · OtherCompany source
POCUS System with AI
Handheld ultrasound with AI guidance for point-of-care diagnostics
Device · EmbeddedCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Backscattered Ultrasonographic Imaging of the Tongue and Outcome in Hypoglossal Nerve Stimulation.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · Jun 1, 2025
Using standardized ultrasound imaging to correlate OSA severity with tongue morphology.Sleep medicine · Aug 1, 2024
Association of Backscattered Ultrasonographic Imaging of the Tongue With Severity of Obstructive Sleep Apnea in Adults.JAMA otolaryngology-- head & neck surgery · Jul 1, 2023
Computerized Cytological Features for Papillary Thyroid Cancer Diagnosis-Preliminary Report.Cancers · Oct 25, 2019
Computer-Aided Diagnostic Technique in 2-Deoxy-2-[18F]fluoro-D-glucose-Positive Thyroid Nodule: Clinical Experience of 74 Non-thyroid Cancer Patients.Ultrasound in medicine & biology · Jan 1, 2019
Quantitative analysis of echogenicity for patients with thyroid nodules.Scientific reports · Oct 20, 2016
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
AmCAD-UTK203555 · 510k · Sep 8, 2021
AmCAD-UOK180867 · 510k · Dec 28, 2018
AmCAD-UVK170069 · 510k · Apr 26, 2017
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
30% of thyroid nodules are indeterminate by conventional ultrasound
AmCAD-UT addresses diagnostic uncertainty in thyroid nodule assessment
80% of OSA cases go undiagnosed
AmCAD-UO enables earlier OSA detection and assessment
50% of breast cancers missed in dense breast tissue
AmCAD-UB enhances detection in challenging cases
Stanford Sleep Center
Research collaboration on OSA assessment using AmCAD-UO
Research results published in Sleep Medicine journal
130+ Healthcare Institutions Worldwide
Adoption of AmCAD-UO and AmCAD-UT for ultrasound AI-powered diagnostics
Products adopted in over 130 healthcare institutions globally, enhancing diagnostic accuracy and reducing overtreatment
Bern University Hospital
Extended clinical use of AmCAD-UO for predicting suitability of OSA treatment
Study published in peer-reviewed journal Otolaryngology–Head and Neck Surgery demonstrating value in predicting treatment success
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Yi-Li Lee
Chairperson / President
C.C. Lee
Founder
Argon Chen
Chief R&D Officer
06 · Company updates
Updates from AmCad BioMed
Recent articles published on AmCad BioMed's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.